Navigation Links
Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
Date:8/31/2011

SAN FRANCISCO, Aug. 31, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced the publication of clinical data on its lead product JX-594 in the journal Nature. For the first time in humans, an oncolytic virus was shown to reproducibly infect, replicate and express transgene products within cancer tissue after intravenous infusion.  Normal tissues were not significantly affected clinically, underscoring the designed selectivity of JX594 for malignant tissue and safety of the product.

"Our platform technology opens up the possibility of selectively expressing multiple transgene products with complementary mechanisms of action at high concentration in tumors systemically. This is a first in medical history," said David Kirn, M.D., president and chief executive officer of Jennerex. "We believe it will take truly innovative, multi-mechanistic approaches to significantly prolong survival, and to potentially cure patients with metastatic solid tumors. JX-594, with its ability to reach tumors systemically after IV infusion, coupled with its three complementary mechanisms of action, represents a bold new approach to the treatment of metastatic cancers."

Dr. Kirn continued, "We look forward to working with our partners on the clinical development of JX-594 in liver, colorectal and other cancer types. We're particularly excited about the TRAVERSE trial, a global, randomized, controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (liver cancer) having failed sorafenib (Nexavar®) treatment, which we plan to initiate this year."

JX-594 replication and engineered transgene expression within solid tumors was evaluated on a Phase 1 dose-escalation trial of intravenous infusion of JX-594. Twenty-three patients with advanced, treatment-refractory
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
(Date:7/29/2015)... -- Research and Markets ( ... "Global Biosimilars Market, 2015 - 2025" ... Biosimilars Market, 2015 - 2025, report provides an ... With the blockbuster biologics losing patent protection and ... being viewed as viable substitutes to the highly ...
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... Focus on Business, NEW YORK, March 4 ... of ExaStore Clustered NAS 2008,designed to meet the most ... environments., "Organizations have seen exponential growth in data ... Arnon Gat, Exanet,President & CEO. "ExaStore 2008 has been ...
... MINO(R) Set to Dramatically Improve Airway Inflammatory Disease ... through Personalized Inflammation Control, NEW PROVIDENCE, N.J., March ... NIOX MINO (http://www.nioxmino.com ), a,hand- held point-of-care device ... by the U.S. Food and Drug Administration (FDA).,Physicians in ...
... - Enerkem today announced progress on,the construction of ... ethanol., The Enerkem plant in Westbury, Canada ... world to make cellulosic ethanol at an industrial ... ethanol from creosoted urban wood,(end-of-life cycle power poles). ...
Cached Biology Technology:Exanet Announces ExaStore 2008 Clustered NAS System 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4Enerkem announces progress on construction of Canada's first cellulosic ethanol plant 2
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... sleep as a healing process that melts away the stresses ... Research has also shown that sleep plays a crucial role ... of anxiety disorders, including posttraumatic stress disorder (PTSD), is the ... to evaluate whether sleep deprivation after exposure to an aversive ...
... CLEVELAND December 7, 2010 Case Western Reserve ... of funding from the National Institutes of Health (NIH), in ... than $6.4 million for four different research endeavors. ... director of the Center for Proteomics and Bioinformatics, and interim ...
... 2010) -- You,ve seen it in movies: the human-like, robot ... This "Terminator" scenario is becoming less far-fetched as recent advances ... of ways to identify damage to a structural system. ... researchers at Arizona State University have created a material that ...
Cached Biology News:Let's not sleep on it 2NIH awards $6.4 million to Case Western Reserve School of Medicine researchers 2NIH awards $6.4 million to Case Western Reserve School of Medicine researchers 3NIH awards $6.4 million to Case Western Reserve School of Medicine researchers 4
Recorder REC-111 single-channel, 1. Category: Chromatography Systems & Accessories, Systems....
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
... Flp-In System creates isogenic cell lines ... of the protein of interest. This ... 3 (click link below). In this ... transferase (CAT) was subcloned into pcDNA5/FRT ...
Biology Products: